Genetic and pharmacological inactivation of soluble epoxide hydrolase ameliorates diet-induced MASH.
Mello Aline A, Hsu Ming-Fo MF, Yang Jun J, Torok Natalie N et al.
Metabolic dysfunction-associated steatohepatitis (MASH) is the most common chronic liver disease worldwide. Pharmacological interventions for MASH remain limited, establishing the need to identify and validate novel therapeutic targets. Soluble epoxide hydrolase (sEH; EPHX2) hydrolyzes anti-inflammatory epoxy fatty acids into less bioactive diols. We investigated the role of hepatic sEH in MASH using genetic and pharmacological approaches. Expression of hepatic EPHX2 was determined in liver samples from MASH patients and control subjects. We also fed control (Ephx2fl/fl) and liver-specific sEH-deficient mice (Alb-Cre; Ephx2fl/fl) either regular chow or a fructose-supplemented fast-food diet (FFD) for 27 weeks. We evaluated metabolic parameters and markers of liver injury, steatosis, inflammation, and fibrosis, as well as oxylipin profiling. Moreover, we treated FFD-fed control mice with the sEH pharmacological inhibitor TPPU in preventive, early, and late therapeutic intervention modalities. We report significant elevation in hepatic EPHX2 in MASH patients compared with controls. Hepatic sEH deficiency improved glucose tolerance, with trends toward lower fasting glucose and fed insulin levels, independent of body weight. Remarkably, hepatic sEH deficiency ameliorated FFD-induced liver injury, steatosis, and lipid dysregulation. Additionally, sEH deficiency mitigated hepatic and systemic inflammation and fibrosis triggered by prolonged FFD feeding. Furthermore, sEH deficiency remodeled the hepatic oxylipin profile and preserved anti-inflammatory epoxides. Importantly, sEH pharmacological inhibition recapitulated these findings, significantly reducing liver injury and steatosis, inflammation, and fibrosis in the FFD across preventive and therapeutic intervention modalities, with the greatest effect in the preventive arm. Together, these findings establish that genetic and pharmacological inactivation of sEH rebalances the oxylipin landscape, enhances the metabolic profile, and ameliorates steatosis, inflammation, and fibrosis in a dietary mouse model of MASH. The concordance between the genetic and pharmacological approaches, along with the efficacy of sEH inhibition across preventive and therapeutic modalities, supports developing sEH-targeted interventions for MASH.